Factor XIII concentrate, human (Corifact)

General information

Class/mechanism: Human factor XIII; in the coagulation cascade, factor XIII is activated by thrombin (factor IIa) to factor XIIIa, which promotes cross-linking of fibrin. Factor XIIIa promotes stabilization of the fibrin clot by cross-linking alpha-2 plasmin inhibitor to the alpha chain of fibrin. Clinically used in patients with congenital factor XIII deficiency.
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Patient drug information

• Factor XIII concentrate, human (Corifact) package insert PDF page 5
• Factor XIII concentrate, human (Corifact) patient drug information (UpToDate)

Also known as

• Generic names: coagulation factor 13, FXIII
• Brand name: Corifact